ACTR-26. A FEASIBILITY STUDY OF THE NATIVIS VOYAGER® SYSTEM IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM)
Barkhoudarian G, Chowdhary S, Blondin N, Kesari S. ACTR-26. A FEASIBILITY STUDY OF THE NATIVIS VOYAGER® SYSTEM IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM). Neuro-Oncology 2018, 20: vi16-vi17. PMCID: PMC6216178, DOI: 10.1093/neuonc/noy148.059.Peer-Reviewed Original ResearchDevice-related adverse eventsAdverse eventsOutcome measuresMaximal tumor debulkingSecond-line therapyProgression-free survivalSecondary outcome measuresFurther prospective studiesPrimary outcome measureStandard of careMulti-center trialInvestigational medical deviceTreatment of glioblastomaClinical utility dataContinual therapyConcurrent therapyOverall survivalProspective studySafety profileTumor debulkingInterim safetyClinical utilityFeasible treatmentPatientsBrain cancer
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply